Generated by AI
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therapies and fluids, supporting more convenient administration and improved patient comfort. The company also develops, manufactures, and commercializes drug-device combination products with advanced auto-injector technology for use in areas such as oncology and other specialty therapeutic settings. In addition to its platform business, Halozyme Therapeutics Inc. markets proprietary products including Hylenex and XYOSTED, and works with pharmaceutical partners to support a range of commercial and development-stage programs. Headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a specialized role in the biopharmaceutical market by providing technologies that help improve how existing medicines are delivered and used.
Website12390 El Camino Real
San Diego, CA, 92130
United States
The latest articles about HALO.
Summary of Oct 23's posts. Generated by AI.
Summary of Aug 6's posts. Generated by AI.
Halozyme Therapeutics (HALO) stock slips as Morgan Stanley downgrades the company, citing valuation concerns following its recent Q3 2026 results. Read more here.
Summary of Jan 5's posts. Generated by AI.
Summary of Feb 17's posts. Generated by AI.
Investors talking about HALO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.